(HRTX)

Reporting relationship: Director
Issuer ticker: HRTX
Reported as of: 30 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 09:15:29 UTC
Prior SEC filing: 12 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Adam Morgan

Key filing fact

Adam Morgan filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 03 Feb 2026.

Key facts

This page summarizes Adam Morgan's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 09:15.

Change

Previous filing in this sequence was filed on 12 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001964335 Primary reporting owner

Morgan Adam

Relationship: Director
Address: 100 REGENCY FOREST DRIVE, SUITE 300, CARY
Signature: /s/ Adam Morgan
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRTX transaction

Common Stock

Award

Transaction value: $0
Shares: +53,960
Change %: +77%
Price: $0.000000
Shares after: 123,737
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1

HRTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,753,290
Date: 30 Jan 2026
Ownership: By Velan Capital Master Fund LP
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

Securities owned directly by Velan Capital Master Fund LP ("Velan Master"). Mr. Morgan, as a managing member of each of Velan Capital Holdings LLC, the general partner of Velan Master, and Velan Capital Management LLC, the general partner of the investment manager of Velan Master, may be deemed to beneficially own the securities owned directly by Velan Master. Mr. Morgan disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that Mr. Morgan is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.